JDRF Announces Expansion of Diabetes Research Program Focused on Preserving Beta Cell Function and Survival

Expanded program intends to accelerate promising ideas from academia into drug development pipeline

New York, March 23, 2011 - The Juvenile Diabetes Research Foundation (JDRF) announced today it has extended its jointly-funded research program with the Johnson & Johnson Corporate Office of Science & Technology (COSAT), which focuses on increasing the development of possible therapeutics that will promote pancreatic beta cell survival and function in individuals with insulin-dependent diabetes.

Preserving beta cell function in individuals at all stages of type 1 diabetes (including at-risk) and even those with insulin-dependent type 2 diabetes could mean a number of things, all of which have the potential to result in a tremendous improvement in the quality of life for those living with the disease:

  • Individuals might develop the disease at a slower rate, or perhaps never even develop the onset of type 1 diabetes
  • Individuals with type 1 diabetes might require less or even no insulin
  • Individuals with type 1 diabetes could potentially have more stable blood sugar levels and reduced risk of hypoglycemia
  • All of the above could mean less risk of short- and long-term complications for those living with the disease

"Developing therapies that will preserve beta cell function could solve one of the fundamental challenges facing researchers. If we can devise treatments to protect functional beta cell mass, it may be possible to slow the progression of type 1 diabetes or prevent it entirely in individuals at risk for the disease," said Patricia Kilian, Ph.D., Director of Beta Cell Regeneration for JDRF.

The joint program funds research to identify specific molecules involved in beta cell survival and death. "If we can then discover and develop drugs that pinpoint these vulnerable areas, we could have a new approach to preserving beta cell function in type 1 diabetes," added Kilian.

Initially announced in December 2009, the program has funded three promising beta cell research projects at leading academic laboratories - and the expanded program intends to double the number of jointly funded projects, thereby accelerating the translation of basic research into potential beta cell therapies for diabetes. 

"This partnership is a prime example of how JDRF is working with companies to translate promising academic research into clinical realities for people with type 1 diabetes," said Karin Hehenberger, M.D., Ph.D., Senior Vice President of Strategic Alliances for JDRF. "It harnesses the strengths of both JDRF and COSAT to identify and support research ideas that may produce novel insights about the disease and new targets to advance the drug discovery and development process."

Bridging the Gap

JDRF's partnership with COSAT is an integral part of a larger organizational initiative that addresses promising areas of research together with industry. Many promising early-stage diabetes technologies discovered within academia often don't move on to become therapies due to a lack of funding. By supporting these novel technologies, we can ensure they make their way through to industry where they can be tested fully and ultimately developed into products for patients.

JDRF and COSAT, working with Johnson & Johnson Pharmaceutical Research & Development, LLC (J&JPRD), are soliciting grant proposals from academia and medical research institutions for one- or two-year projects. Funding recommendations will be led by a combined review committee consisting of representatives from JDRF, COSAT, and J&JPRD, with oversight from a Scientific Advisory Board and JDRF volunteers.


About JDRF

JDRF is the leading global organization focused on type 1 diabetes (T1D) research. Driven by passionate, grassroots volunteers connected to children, adolescents, and adults with this disease, JDRF is now the largest charitable supporter of T1D research. The goal of JDRF research is to improve the lives of all people affected by T1D by accelerating progress on the most promising opportunities for curing, better treating, and preventing T1D. JDRF collaborates with a wide spectrum of partners who share this goal.

Since its founding in 1970, JDRF has awarded more than $1.6 billion to diabetes research. Past JDRF efforts have helped to significantly advance the care of people with this disease, and have expanded the critical scientific understanding of T1D. JDRF will not rest until T1D is fully conquered. 

Lets turn type one into type none